SCHEMBL21552833

SCHEMBL21552833

O=C(O)/C=C/c1cn(-c2ccc(-c3ncccn3)cc2)c(=O)c(N2CC3(COC3)C2)n1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.35
MGLL Q99685 1/20 0.34
GRIA1 P42261 2/20 0.32
PDE10A Q9Y233 1/20 0.32
HDAC4 P56524 1/20 0.32
ESR1 P03372 1/20 0.32
PFKFB3 Q16875 1/20 0.31
TNKS O95271 1/20 0.31
USP2 O75604 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPK1 P28482 1/20 0.31
CYP2C19 P33261 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HIF1A Q16665 1/20 0.31
PIN1 Q13526 1/20 0.30
PIK3R1 P27986 2/20 0.30
PIK3CA P42336 2/20 0.30
MTOR P42345 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21564485 0.87 PFKFB3 (0.38) SYKPFKFB3PIK3R1PIK3CAMTOR
SCHEMBL21553154 0.85 GRIA1 (0.36) SYKMGLLGRIA1HDAC4ESR1
SCHEMBL21552890 0.82 PTGS2 (0.37) SYKMGLLHDAC4PFKFB3
SCHEMBL30719413 0.77 GRIA1 (0.41) SYKMGLLGRIA1PDE10AHDAC4
SCHEMBL21552844 0.77 SYK (0.37) SYKGRIA1TNKS
SCHEMBL21552994 0.77 SYK (0.37) SYKMGLLGRIA1PDE10APIK3R1
SCHEMBL21552964 0.74 PFKFB3 (0.38) SYKPFKFB3PIK3R1PIK3CAMTOR
SCHEMBL21564807 0.73 MTOR (0.43) PIK3R1PIK3CAMTOR
SCHEMBL21564785 0.73 GABRA2 (0.38) GRIA1PFKFB3
SCHEMBL21552963 0.69 MGLL (0.34) SYKMGLLPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A SYK 2651/4885MGLL 4641/4885GRIA1 2609/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A SYK 2651/4885MGLL 4641/4885GRIA1 2609/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A SYK 2621/4885MGLL 4582/4885GRIA1 2330/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A SYK 2651/4885MGLL 4641/4885GRIA1 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.